摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1S,6R,8R,9R)-8,9-dihydroxy-8,9-O-isopropylidene-2,7-dioxabicyclo[3.4.0]non-4-ene | 226919-75-1

中文名称
——
中文别名
——
英文名称
(1S,6R,8R,9R)-8,9-dihydroxy-8,9-O-isopropylidene-2,7-dioxabicyclo[3.4.0]non-4-ene
英文别名
(1S,2R,6R,8R)-4,4-dimethyl-3,5,7,12-tetraoxatricyclo[6.4.0.02,6]dodec-9-ene
(1S,6R,8R,9R)-8,9-dihydroxy-8,9-O-isopropylidene-2,7-dioxabicyclo[3.4.0]non-4-ene化学式
CAS
226919-75-1
化学式
C10H14O4
mdl
——
分子量
198.219
InChiKey
XFNVOIOMPJFKIV-BZNPZCIMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    14
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.8
  • 拓扑面积:
    36.9
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Chiron Approach to Formal Synthesis of 8,9-dideoxyneodysiherbaine (MSVIII-19)
    作者:Alma Sanchez-Eleuterio、Virginia M. Mastranzo、Leticia Quintero、Fernando Sartillo-Piscil
    DOI:10.2174/1570178614666170307091943
    日期:2017.6.8
    Background: The synthesis of biologically active model compounds represents a valuable tool for medicinal chemistry. In this regard, the synthesis of MSVII-19, a structurally simplified model compound of Dysiherbaine, developed by the group of Sasaki, was synthesized with the intention of preparing a powerful agonist or antagonist of glutamate receptor. Therefore, the synthesis of an advanced intermediate in the Sasaki’s synthesis of MSVIII-19 is reported. Methods: Taking advantage of the furanose ring of the diacetone-D-glucose (DAG), the cis-fused hexahydrofuro[3,2-b]pyran ring system of the title compound was constructed by featuring two protocols: SHOWO (sequential hydrolysis-oxidation-Wittig olefination) and RCM (ring closing metathesis). Then, by applying a combined allylation at the anomeric position and a Pd-catalyzed double bond isomerization reaction, the methyl ester group in 1b was installed. Results: The synthesis of an advanced intermediate of MSVIII-19 involves three key procedures: a) SHOWO (sequential hydrolysis-oxidation-Wittig olefination) protocol; b) RCM (ring closing metathesis) reaction; y c) the nucleophilic substitution at the anomeric position. Additionally, with the use of a cheaper starting material (DAG) than that used in the previous synthesis (tri-O-acetyl-D-glucal). The current synthesis is truly competitive with that reported by the Sasaki group. Conclusion: A concise formal total synthesis of the advanced intermediate of MSVIII-19 was achieved. (Current synthesis: 14 steps; previous synthesis 20 steps).
    背景:生物活性模型化合物的合成是药物化学中的一项重要工具。在这方面,由佐佐木团队开发的结构简化的Dysiherbaine模型化合物MSVIII-19的合成旨在制备强效的谷酸受体激动剂或拮抗剂。因此,报告了佐佐木合成MSVIII-19中一个高级中间体的合成。 方法:利用二乙酮-D-葡萄糖DAG)的呋喃环,通过两个步骤构建了标题化合物的顺式融合六氢呋喃[3,2-b]喃环系统:SHOWO(顺序解-氧化-Wittig烯化)和RCM(环闭合烯烃交换反应)。然后,通过在异头位置应用联合烯丙基化和Pd催化的双键异构化反应,以安装1b中的甲基酯基团。 结果:MSVIII-19高级中间体的合成涉及三个关键程序:a) SHOWO(顺序解-氧化-Wittig烯化)协议;b) RCM(环闭合烯烃交换)反应;c) 在异头位置的亲核取代。此外,使用了比先前合成中使用的起始材料(tri-O-乙酰-D-葡萄糖醛)更便宜的起始物质(DAG)。目前的合成与佐佐木团队报告的合成相比,具有较强的竞争力。 结论:成功实现了MSVIII-19高级中间体的简洁正式总合成。(当前合成:14步;先前合成:20步)。
  • Sequential Ring-Closing Metathesis and Nitrone Cycloaddition on Glucose-Derived Substrates:  A Divergent Approach to Analogues of Spiroannulated Carbanucleosides and Conformationally Locked Nucleosides
    作者:Sk. Sahabuddin、Ashim Roy、Michael G. B. Drew、Biswajit Gopal Roy、Basudeb Achari、Sukhendu B. Mandal
    DOI:10.1021/jo0606554
    日期:2006.8.1
    6-di-O-isopropylidene-α-d-allofuranose was judiciously manipulated for preparing suitable synthons, which could be converted to a variety of isoxazolidino-spirocycles and -tricycles through the application of ring-closing metathesis (RCM) and intramolecular nitrone cycloaddition (INC) reactions. Cleavage of the isoxazolidine rings of some of these derivatives by tranfer hydrogenolysis followed by coupling
    碳水化合物衍生的底物3- C-烯丙基-1,2:5,6-二-O-异亚丙基-α- d明智地操纵了-呋喃喃糖以制备合适的合成子,通过应用闭环复分解(RCM)和分子内硝酮环加成(INC)反应可将其合成为各种异恶唑烷-螺环和-三环。通过转移氢解裂解这些衍生物中的一些异恶唑烷环,然后将生成的基官能团与5-基-4,6-二氯嘧啶偶联,提供了相应的氯嘧啶核苷,它们被加工成螺环化的碳核苷并构象锁定了双环[2.2。]。 1]庚烷/氧杂双环[3.2.1]辛烷核苷。但是,使用较高的温度环化一个嘧啶嘧啶,导致二甲氨基嘌呤类似物成为唯一产物,
  • Haque, Azizul; Panda, Jagannath; Ghosh, Subrata, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1999, vol. 38, # 1, p. 8 - 9
    作者:Haque, Azizul、Panda, Jagannath、Ghosh, Subrata
    DOI:——
    日期:——
  • A convenient route to cis- and trans-fused bicyclic ethers by ruthenium mediated ring-closing metathesis of diene and enyne carbohydrate derivatives
    作者:Michiel A. Leeuwenburgh、Camiel Kulker、Howard I. Duynstee、Herman S. Overkleeft、Gijsbert A. van der Marel、Jacques H. van Boom
    DOI:10.1016/s0040-4020(99)00296-3
    日期:1999.7
    A general approach towards the construction of highly functionalised pyranopyran and pyranofuran systems via Grubbs [Ru] catalysed ring-closing metatheses of neighbouring vinyl-O-allyl and vinyl-O-propargyl functions on monosaccharide scaffolds is described. (C) 1999 Elsevier Science Ltd. All rights reserved.
查看更多

同类化合物

马桑宁内酯 薁并[6,5-b]呋喃-2,4-二酮,十氢-5-(3-羟基丙氧基)-3a,4a-二甲基- 苦毒浆果[木防已属] 苦亭 艾瑞布林中间体 艾瑞布林 甲磺酸艾日布林 木防己苦毒宁 呋喃并[4,3,2-ij][2]苯并吡喃-2,7-二酮,2a,3,4,6,8a,8b-六氢-6-甲基-5-[(1S)-1,3,3-三甲基环己基]-,(2aR,6R,8aS,8bR)- 全内酯 二氢苦毒宁 6-甲基-4-氧代-4H-呋喃并[3,2-c]吡喃-3-甲酰氯 6-(4-羟基苯基)-2,3,3-三甲基-2H-呋喃并[5,4-b]吡喃-4-酮 4H-呋喃并[2,3-c]吡喃基莫匹罗星钠 3-甲基2H-呋喃并[2,3-c]吡喃-2-酮 3,5-二甲基2H-呋喃并[2,3-c]吡喃-2-酮 2H-呋喃并[2,3-c]吡喃-2-酮 2-[(1E,3E)-己-1,3-二烯基]-2,6-二甲基-5,6-二氢呋喃并[5,4-b]吡喃-3,4-二酮 (3aS,5S,6R,9E,14R,15R,15aR)-2,3,3a,4,5,6,7,8,11,12,13,14,15,15alpha-十四氢-6,10,14-三甲基-3-亚甲基-2-氧代-5,15-环氧环十四烷并[b]呋喃-6-醇乙酸酯 (3aR,4S,7aR)-4-羟基-3,3a,4,7a-四氢呋喃并[5,4-b]吡喃-2-酮 (3aα,3bβ,6aβ,7aα)-(+/-)-hexahydro-6-hydroxy-3a-(phenylmethyl)difuro<2,3-b:3',4'-d>furan-2(3H)-one (2R,3aS,4S,6S,7aR)-3a-benzyloxy-6-ethynyl-2-methoxy-4-p-methoxybenzyloxyhexahydrofuro[2,3-b]pyran (1R,2S,6S,7S)-5,6-Dimethoxy-8-oxo-3,9-dioxa-tricyclo[5.2.2.02,6]undeca-4,10-diene-10-carboxylic acid methyl ester N3,5'-Cyclo-2',3'-O-isopropyliden-8-oxyguanosin (3aR,4aR,7aS,8aS)-2-Thioxo-hexahydro-furo[3',4':4,5]benzo[1,2-d][1,3]dioxol-5-one 9-(3',5'-O-Isopropyliden-2-keto-β-D-xylofuranosyl)-adenin (1aR,1bS,4aS,5aS)-1a-Isopropyl-hexahydro-1,4-dioxa-cyclopropa[a]pentalen-3-one [(3aR,4S,6R,7S,7aR)-7-acetyloxy-2-oxo-4-phenylsulfanyl-3,3a,4,6,7,7a-hexahydropyrano[3,4-d][1,3]oxazol-6-yl]methyl acetate (2R,3R,3aS,6R,7R,7aR)-7-azido-6-methoxy-2-phenylsulfanyl-hexahydrofuro[3,2-b]pyran-3-ol 7-Dihydroxymethyl-O1,O2-isopropyliden-3,7-anhydro-6-desoxy-D-glucofuranose (1S,2S,6S,7R)-5,6-Dimethoxy-8-oxo-3,9-dioxa-tricyclo[5.2.2.02,6]undeca-4,10-diene-10-carboxylic acid methyl ester (2R,3S)-2-Methyl-4-oxo-oxetane-3-carboxylic acid (1R,5S)-6-methylene-3-oxo-bicyclo[3.2.1]oct-1-ylmethyl ester 3-C-(3,4,6-tri-O-acetyl-2-deoxy-2-tetrachlorophthalimido-β-D-glucopyranosyl)-1-propene (2R,4aR,5aS,8aS,9S,9aR)-5a-methoxy-7-oxo-2-phenyloctahydrofuro[2',3':5,6]pyrano[3,2-d][1,3]dioxin-9-yl acetate (4R,5E,7R,9S,10S,11E,14S)-9-((benzyloxy)methoxy)-4,10-bis((tert-butyldimethylsilyl)oxy)-7-(dimethoxymethyl)-14-(furan-3-yl)-6,12-dimethyloxacyclotetradeca-5,11-dien-2-one 3-Furan-3-yl-8-methyl-5-(4,5,6,7-tetrahydro-isobenzofuran-4-yl)-2,7-dioxa-bicyclo[3.2.1]octane methyl 2,3"-anhydro-4,6-O-benzylidene-3-C-[2,2-dihydroxyethyl]-α-D-glucopyranoside (3aR,5S,6S,7aR)-5-((R)-but-3-en-2-yl)-6-hydroxyhexahydro-2H-furo[3,2-b]pyran-2-one 7-(3-Furan-3-yl-8-methyl-2,7-dioxa-bicyclo[3.2.1]oct-5-yl)-1,3,4,5,6,7-hexahydro-isobenzofuran-1-ol